Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
Cryoport, Inc. filed this Current Report on Form 8-K on June 10, 2014, to disclose the entry into a material definitive agreement and the recent sale of unregistered securities. The company is incorporated in Nevada and is based in Lake Forest, California.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $432,160 from the sale of securities.
- Net Proceeds: Approximately $360,979 after estimated cash offering expenses.
- Securities Issued: 36,013 Units sold at $12.00 per Unit.
- Unit Composition: One share of Class A Convertible Preferred Stock and one warrant to purchase eight shares of Common Stock.
- Warrant Terms: Exercise price of $0.50 per share; immediately exercisable; expiration date of March 31, 2019.
- Placement Agent Fees: 10% commission plus a 3% non-accountable finance fee on gross proceeds, plus legal expense reimbursement up to $40,000.
- Agent Warrants: Placement agent (Emergent Financial Group, Inc.) received warrants to purchase three shares of Common Stock per Unit issued.
Material Changes and Use of Proceeds
The primary material change is the capital raise via private placement. The company intends to use the net proceeds for working capital purposes. The offering period for new investors was extended through July 14, 2014. This filing does not provide comparative financial metrics such as revenue, profit, or cash flow for the period.
Outlook, Risks, and Contingencies
The transaction was conducted under the exemption provided by Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933. The filing notes that the summary of terms is qualified by reference to the full text of the Subscription Agreements and warrants, which are to be filed as exhibits with the Form 10-K for the fiscal year ended March 31, 2014. No specific forward-looking guidance or risk factors beyond the standard securities offering disclosures are detailed in this specific 8-K text.
Key Facts for Investor Verification
- Verify the dilution impact of the 36,013 Units issued, specifically the potential issuance of up to 288,104 shares of Common Stock upon full warrant exercise.
- Confirm the exact amount of cash offering expenses deducted to reach the net proceeds of approximately $360,979.
- Review the full Subscription Agreements and warrant terms in the upcoming Form 10-K filing for the fiscal year ended March 31, 2014.
- Monitor the status of the extended offering period ending July 14, 2014, for potential additional capital raises.